

Attorney Docket No.: RTS-0345  
Inventors: Borchers and Dobie  
Serial No.: 10/007,010  
Filing Date: December 4, 2001  
Page 2

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

Claim 1 (currently amended): A compound 8 to 80 nucleobases in length targeted to nucleobases 67 through 144 of a 5'-untranslated region, nucleobases 258 through 1684 of a coding region, a stop codon region, or a 3'-untranslated region of a nucleic acid molecule of SEQ ID NO: 3 encoding hematopoietic cell protein tyrosine kinase, ~~or an intron 5 region, an intron-exon junction region, or an intron 9 region of a nucleic acid molecule of SEQ ID NO: 10 encoding hematopoietic cell protein tyrosine kinase,~~ wherein said compound specifically hybridizes with one of said regions and inhibits the expression of hematopoietic cell protein tyrosine kinase.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Attorney Docket No.: **RTS-0345**  
Inventors: **Borchers and Dobie**  
Serial No.: **10/007,010**  
Filing Date: **December 4, 2001**  
Page 3

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Attorney Docket No.: RTS-0345  
Inventors: Borchers and Dobie  
Serial No.: 10/007,010  
Filing Date: December 4, 2001  
Page 4

Claim 15 (previously presented): A method of inhibiting the expression of hematopoietic cell protein tyrosine kinase in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 1 so that expression of hematopoietic cell protein tyrosine kinase is inhibited.

Claims 16-20 (canceled).